Navigation Links
Addition of bevacizumab to initial treatment for brain tumors does not extend patients' lives
Date:6/2/2013

Results of a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG) determined that adding bevacizumab to initial treatment for glioblastoma (GBM) did not improve patient overall survival or progression-free survival,. Results were reported June 2 during the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting.

Chicago, IllinoisGBM is the most common primary malignant brain tumor in adults and, despite treatment advances in recent years, the average survival of patients enrolled in clinical trials is less than 16 months and few patients live beyond five years. GBM is characterized by angiogenesisthe formation of new blood vessels that support tumor growth stimulated by the GBM-produced vascular endothelial growth factor A (VEGF-A). Bevacizumab is a monoclonal antibody that targets VEGF-A production to block the growth of tumor-derived blood vessels. "Clinical trials evaluating the addition of bevacizumab to standard treatment for recurrent glioblastoma demonstrated clinical benefit and led to the drug's FDA approval for this indication," says Mark Gilbert, MD, RTOG 0825 Principal Investigator and professor of neuro-oncology at The University of Texas MD Anderson Cancer Center, Houston, Texas. "Additionally, compelling preclinical data suggest that anti-angiogenic targeted therapies may normalize the tumor's rapidly forming and underdeveloped blood vessels, resulting in improved oxygen and chemotherapy delivery to the tumor and potentially enhancing radiotherapy and chemotherapy treatment," explains Gilbert. The RTOG 0825 study tested this hypothesis.

Six hundred and thirty-seven adult study participants were enrolled in the multicenter trial and randomized into one of two study arms, with treating physicians blinded to treatment assignment. All participants were treated with standard radiotherapy (RT) (60 Gy) and daily temozolomide. Bevacizumab (experimental arm) or a plac
'/>"/>

Contact: Shawn Farley
PR@acr.org
703-648-8936
American College of Radiology
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Radiologists study necessity of additional imaging recommendations in PET/CT oncologic reports
2. Warmer soils release additional CO2 into atmosphere; Effect stabilizes over longer term
3. Additional research must be done to ensure safety of pit latrines, new study says
4. Evolution Marketing Research Grows its Practice with Addition of Three Key Industry Professionals
5. New data suggests HIV superinfection rate comparable to initial HIV infection
6. NLST: CT detects twice as many lung cancers as X-ray at initial screening exam
7. Breakthroughs in Chikungunya research from A*STAR spell new hope for better treatment and protection
8. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
9. Genetic research develops tools for studying diseases, improving regenerative treatment
10. Step forward in research into new treatments for brain edema
11. Marshall University study may lead to new treatments for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2015)... DUBLIN , July 23, 2015 ... the addition of the "Global Outlook of ... their offering. The global biometrics ... both public and commercial applications owing to the ... will witness a transformation that enhances the growth ...
(Date:7/20/2015)... , July 20, 2015  Acuity Market Intelligence,s ... The Convergence of Commerce and Privacy" forecasts that ... biometric apps will be downloaded to smart mobile ... mobile biometrics market is projected to generate more ... during the seven-year forecast period.    ...
(Date:7/9/2015)... , July 07, 2015 ... the addition of the "Biometrics for Banking; ... 2015-2020" report to their offering. ... contributor to this growth and the forecast is ... in revenue for companies involved in delivering biometric ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... good, but sometimes its better to be lucky. Ecologist ... St. Louis, had just completed a census of snakes at ... flood of 1993 deluged the area, putting the preserve at ... with a rare opportunity: His collected data and the flood ...
... have developed tools to help solve two of the main ... to quickly test stem cell response to different drugs or ... viable stem cells to study from only a few available ... of stems cells on devices the size of a standard ...
... several repeat operations as they grow, since the since ... for bigger ones. Researchers at Childrens Hospital Boston have ... the lab from a patients own cells. In ... describe making pulmonary valves through tissue engineering. These valves, ...
Cached Biology News:Ecologist finds dire devastation of snake species following floods of '93, '95 2Ecologist finds dire devastation of snake species following floods of '93, '95 3Ecologist finds dire devastation of snake species following floods of '93, '95 4Putting stem cell research on the fast track 2Putting stem cell research on the fast track 3Putting stem cell research on the fast track 4A step toward tissue-engineered heart structures for children 2
(Date:7/27/2015)... ... July 27, 2015 , ... BlueInGreen® announced the addition of ... bring the world’s most efficient gas dissolution technology to all of Florida, excluding ... the industrial and municipal markets. With offices located in Sarasota, Sebring and Melbourne ...
(Date:7/27/2015)... ... July 27, 2015 , ... Visual Assay was named as a finalist for ... innovative technologies and services of the past year. More than 70 judges selected the ... winners will be announced at the 2015 R&D 100 Awards Dinner on November 13 ...
(Date:7/24/2015)... 2015 Equity Research Institute has ... (NASDAQ: PDLI ), Arena Pharmaceuticals Inc. (NASDAQ: ... Biotherapeutics Inc. (NASDAQ: NWBO ), and Acorda Therapeutics ... PDL BioPharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=PDLI ... at 5,146.41, down 0.49%, the Dow Jones Industrial Average ...
(Date:7/24/2015)... China , July 24, 2015 ... manufacturing platform , Expands product offering for chronic ... unmet medical needs in diabetes-related complications and dermatology ... 3SBio Inc., (HKEX:1530) ("3SBio" or ,the Company"), a leading ... researching, developing, manufacturing and marketing biopharmaceutical products, today announced ...
Breaking Biology Technology:BlueInGreen Brings Water Treatment Technology to Florida 2Visual Assay® Named Finalist in 53rd Annual R&D 100 Awards 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 53SBio Acquires Zhejiang Wansheng Pharmaceutical 23SBio Acquires Zhejiang Wansheng Pharmaceutical 33SBio Acquires Zhejiang Wansheng Pharmaceutical 4
... Reportlinker.com announces that a new market research report ... Gene Therapy - technologies, markets and companies ... Summary Gene therapy can be ... material to specific target cells of a patient ...
... Nov. 30, 2011  Rhythm announced today that Lex Van ... Scientific Officer. Dr. Van der Ploeg brings to Rhythm ... obesity, metabolic diseases, and other therapeutic areas. ... of the metabolic pathways we are targeting with our ...
... 2011 Reportlinker.com announces that a new ... catalogue: Animal Biotechnology - ... http://www.reportlinker.com/p0203534/Animal-Biotechnology---Technologies-Markets-and-Companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biotechnology Summary ... evaluates animal biotechnology and its application in ...
Cached Biology Technology:Gene Therapy - Technologies, Markets and Companies 2Gene Therapy - Technologies, Markets and Companies 3Gene Therapy - Technologies, Markets and Companies 4Gene Therapy - Technologies, Markets and Companies 5Gene Therapy - Technologies, Markets and Companies 6Gene Therapy - Technologies, Markets and Companies 7Gene Therapy - Technologies, Markets and Companies 8Gene Therapy - Technologies, Markets and Companies 9Gene Therapy - Technologies, Markets and Companies 10Gene Therapy - Technologies, Markets and Companies 11Gene Therapy - Technologies, Markets and Companies 12Gene Therapy - Technologies, Markets and Companies 13Gene Therapy - Technologies, Markets and Companies 14Gene Therapy - Technologies, Markets and Companies 15Gene Therapy - Technologies, Markets and Companies 16Gene Therapy - Technologies, Markets and Companies 17Gene Therapy - Technologies, Markets and Companies 18Gene Therapy - Technologies, Markets and Companies 19Gene Therapy - Technologies, Markets and Companies 20Gene Therapy - Technologies, Markets and Companies 21Rhythm Names Lex Van der Ploeg Chief Scientific Officer 2Animal Biotechnology - Technologies, Markets and Companies 2Animal Biotechnology - Technologies, Markets and Companies 3Animal Biotechnology - Technologies, Markets and Companies 4Animal Biotechnology - Technologies, Markets and Companies 5Animal Biotechnology - Technologies, Markets and Companies 6Animal Biotechnology - Technologies, Markets and Companies 7Animal Biotechnology - Technologies, Markets and Companies 8Animal Biotechnology - Technologies, Markets and Companies 9Animal Biotechnology - Technologies, Markets and Companies 10Animal Biotechnology - Technologies, Markets and Companies 11Animal Biotechnology - Technologies, Markets and Companies 12Animal Biotechnology - Technologies, Markets and Companies 13Animal Biotechnology - Technologies, Markets and Companies 14
One-step, microplate or cuvet, colorimetric, detection range 0.3 g/dL to 5 g/dL. Procedure: 5 min....
The Varian 4000 GC/MS system offers three easily switchable ionization configurations: internal ionization (II), external ionization (EI) or hybrid chemical ionization (CI)...
One-step, microplate or cuvet, colorimetric, detection range 0.04% to 4%. Procedure: 30 min....
One-step, microplate or cuvet, colorimetric, linear detection range 0.7 mg/dL to 35 mg/dL. Procedure: 5 min....
Biology Products: